Condition: Glioblastoma · Sponsor: University Hospital Tuebingen
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation isotoxically. The goal is improved survival without significantly increasing side effects. The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per fraction.
This description comes directly from the study's public registry record.
Barbara Gehler, Dr. med. · +49 7071 29 83420 · pride_tuebingen@med.uni-tuebingen.de
Always discuss trial participation with your own doctor first.
| Department of Radiation Oncology, University Hospital Augsburg | Augsburg, Germany | Recruiting |
| Department of Radiation Oncology, University Hospital Köln | Cologne, Germany | Recruiting |
| Department of Radiation Oncology, University Hospital Frankfurt | Frankfurt, Germany | Recruiting |
| Department of Radiation Oncology, University Hospital Freiburg | Freiburg im Breisgau, Germany | Recruiting |
| Department of Radiation Oncology, University Hospital Leipzig | Leipzig, Germany | Recruiting |
| Department of Radiation Oncology, Medical Faculty Mannheim | Mannheim, Germany | Recruiting |
| Department of Radiation Oncology, University Hospital, LMU Munich | Munich, Germany | Recruiting |
| Department of Neurology, University Hospital Regensburg | Regensburg, Germany | Recruiting |
| Department of Radiation Oncology | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05871021